Plus Therapeutics' CNSide Study Shows 40% Reduction in LM Healthcare Costs
PSTV•Plus Therapeutics' CNSide CSF assay analysis with Harvard shows earlier LM diagnosis cuts healthcare costs by roughly 33%-47%, driven by reduced hospitalizations and treatment precision. The assay earned Blue Ribbon recognition at ISPOR and secured new payer agreements supporting U.S. commercialization.
1. Economic Impact Analysis Findings
Plus analysis with Harvard T.H. Chan School of Public Health estimated that earlier detection and management of leptomeningeal metastases using CNSide reduced healthcare costs by 33%-47%. The study highlighted median inpatient admission costs of ~$20,000 (IQR $10,000–$30,000) and total LM-related expenses exceeding $100,000 per month.
2. Top-5% Recognition at ISPOR Meeting
The cost-of-care poster on CNSide received Blue Ribbon status at the ISPOR 2026 Annual Meeting, an honor reserved for the top 5% of scientific presentations, validating the study’s methodology and findings among health economics experts.
3. Payer Support Accelerates U.S. Commercial Rollout
Following the study, Plus finalized new payer agreements in the United States, enabling reimbursement pathways for the CNSide assay and positioning the company to expand market access and enhance diagnostic adoption in CNS cancer care.
